Zobrazeno 1 - 10
of 459
pro vyhledávání: '"M Gramatzki"'
Autor:
D Gramatzki, T Weiss, L Hänsch, M Silginer, E J Rushing, P Roth, M Gramatzki, M Peipp, M Weller
Publikováno v:
Neuro-Oncology. 24:ii53-ii53
Background CD317 is an interferon-inducible cell surface receptor expressed in several solid cancer types. HM1.24-ETA’ is a small immunotoxin with a CD317 single-chain variable fragment (svFv) antibody fused to a truncated version of Pseudomonas ae
Autor:
S. Bringhen, A. Milan, M. D'Agostino, C. Ferri, R. Wäsch, F. Gay, A. Larocca, M. Offidani, S. Zweegman, E. Terpos, H. Goldschmidt, M. Cavo, H. Ludwig, C. Driessen, H. W. Auner, J. Caers, M. Gramatzki, M. A. Dimopoulos, M. Boccadoro, H. Einsele, P. Sonneveld, M. Engelhardt
Publikováno v:
Bringhen, S, Milan, A, D'Agostino, M, Ferri, C, Wäsch, R, Gay, F, Larocca, A, Offidani, M, Zweegman, S, Terpos, E, Goldschmidt, H, Cavo, M, Ludwig, H, Driessen, C, Auner, H W, Caers, J, Gramatzki, M, Dimopoulos, M A, Boccadoro, M, Einsele, H, Sonneveld, P & Engelhardt, M 2019, ' Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension ', Journal of Internal Medicine, vol. 286, no. 1, pp. 63-74 . https://doi.org/10.1111/joim.12882
Journal of Internal Medicine, 286(1), 63-74. Wiley-Blackwell
Journal of Internal Medicine, 286(1), 63-74. Wiley-Blackwell Publishing Ltd
Journal of Internal Medicine, 286(1), 63-74. Wiley-Blackwell
Journal of Internal Medicine, 286(1), 63-74. Wiley-Blackwell Publishing Ltd
The novel proteasome inhibitor carfilzomib alone or in combination with other agents is already one of the standard therapies in relapsed and/or refractory multiple myeloma (MM) patients and produces impressive response rates in newly diagnosed MM as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f318e6b23b3a481ef966a717062861b
https://research.vumc.nl/en/publications/f1597bf4-4e03-47b9-94cc-07e2a74622ca
https://research.vumc.nl/en/publications/f1597bf4-4e03-47b9-94cc-07e2a74622ca
Publikováno v:
ISBT Science Series. 5:141-147
Harvest, production, storage and release of cellular products are regulated by international guidelines like the EU guidelines 2004/23/EC or 2006/17/EC. In addition, worldwide effective guidelines exist with the FACT-JACIE standards. As cellular prod
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Suleyman Yedibela, Thomas Reck, Gerald Niedobitek, Martin Gramatzki, Roland Repp, Werner Hohenberger, Rudolf Ott, M. Gramatzki
Publikováno v:
Transplant International. 16:197-201
Autor:
R. Kühn, Martin J. Glennie, J.R. Kalden, J.G.J. van de Winkel, B. Stockmeyer, M. Gramatzki, D. Els¨Asser, H. Stadick, K.M. Schrott, T. Valerius
Publikováno v:
The Journal of Urology. :707-712
Purpose: Monoclonal antibodies are a novel treatment option for certain tumor patients. We evaluated the potential of antibody derivatives against epidermal growth factor receptor and G250, which are 2 candidate antigens on renal cell carcinoma, to r
Publikováno v:
Immunology today. 7(7-8)
There has been a remarkable increase in understanding of the control of immune reactions and hemopoietic stem cell proliferation by cytokines. At a recent meeting ∗ ∗An international workshop was held at the University of Erlangen, FRG, in associ
Autor:
M. Gramatzki
Publikováno v:
Drug Research. 65:S21-S22
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
T. Valerius, M. Gramatzki
Publikováno v:
Der Internist. 38:1055-1062
In dem Mase, in dem einerseits Tumorzellantigene besser definiert und andererseits spezifische Antikorper produziert werden konnen, ruckt der Wunschtraum einer Immuntherapie von Malignomen naher. Diese Therapieoption war viele Jahrzehnte immer wieder